Compare Merck & Co., Inc. (MRK) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Trip.com Group Ltd — how do they compare? Merck & Co., Inc. trades at $126.14 (market cap $307.25B), while Trip.com Group Ltd trades at $43.78 (market cap $28.12B). The key difference: Merck & Co., Inc. is far larger — about 10.9× Trip.com Group Ltd's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | TCOM | |
|---|---|---|
Market Cap | $307.25B | $28.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.52 | $78.96 |
52-Week Low | $77.60 | $39.84 |
Enterprise Value | $350.66B | $20.82B |
Dividend Yield | 2.73% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
